Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 5S ribosomal pseudogene 323 (RNA5SP323) is classified as a processed pseudogene, specifically one of many related to the 5S ribosomal RNA gene, which is a highly conserved structural RNA component of the large ribosomal subunit[2][5]. As a pseudogene, RNA5SP323 does not encode a functional RNA or protein product due to disabling mutations and lack of necessary regulatory elements for transcription[2]. Processed pseudogenes like RNA5SP323 generally arise via reverse transcription and reintegration of RNA transcripts, often lacking introns and original regulatory elements, and are non-functional remnants dispersed throughout the genome[2]. Pseudogenes are not usually considered therapeutic targets—they do not encode active enzymes, receptors, or other druggable proteins. However, recent research has identified functional roles for some expressed pseudogenes in gene regulation or disease contexts, including cancer, but there is no evidence that RNA5SP323 specifically is functional or disease-associated[8]. RNA5SP323 is not a valid therapeutic target (e.g., not a receptor, enzyme, or transporter)[2][5]. It is a probable genomic annotation artifact, listed as a pseudogene with no current evidence for coding or regulatory function[2][4]. There is no evidence for drug interactions, biomarker utility, or a defined molecular mechanism[2][3][5]. The parental gene, 5S ribosomal RNA, is a critical component of ribosomes involved in protein synthesis and ribosome assembly[3][5]; however, the pseudogene itself does not contribute to these functions. Pseudogene expression (generally, not for this specific pseudogene) is a subject of cancer biology research as potential long non-coding RNAs or regulatory RNAs, but this is not established for RNA5SP323[8]. This entry is not a classical therapeutic target, is a non-functional pseudogene, and does not warrant inclusion in a database of druggable proteins or functional molecular targets. There is no evidence for its direct biological or medical relevance beyond being a genomic relic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 5S ribosomal pseudogene 323 (RNA5SP323).